New drug combo aims to shrink tumors before lung cancer surgery
NCT ID NCT07182708
Summary
This study is testing whether a high dose of the drug firmonertinib, combined with bevacizumab, can effectively shrink tumors before surgery in patients with a specific type of lung cancer (EGFR-mutated, non-small cell). The goal is to see if this pre-surgery treatment helps remove more of the cancer and improves outcomes. The study will enroll about 62 adults with stage II-IIIB lung cancer that is planned for surgical removal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.